Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
MONTROUGE, France, Feb. 8, 2016 -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Vice President of Finance, Investor Relations & Strategy, will present at LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th, 2016 at
3:55 pm ET at the Waldorf Astoria Hotel in New York, NY.
A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations. A replay will also be available 48 hours after the event.
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.
About DBV Technologies
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
| DBV Technologies Contacts | |
|
Nathalie Donne Director, Corporate Communication & Business Development Tel. : +33 (0)1 55 42 78 72 [email protected] |
Susanna Mesa VP of Finance, Investor Relations & Strategy Tel. : +1 212-271-0861 [email protected] |
|
DBV Technologies Media Contacts US & Europe |
|
|
Marion Janic Rooney & Associates Tel. : +1 212-223-4017 [email protected] |
Caroline Carmagnol Alize RP - Relation Presse Tel. : +33 (0)6 64 18 99 59 [email protected] |
PDF Version http://hugin.info/156437/R/1984165/727364.pdf
HUG#1984165
